Kilitch Drugs India Ltd
Kilitch Drugs India Ltd (KILITCH) last reported results for the quarter ended Jun 2026, with sales of ₹44.88 crore and net profit of ₹1.96 crore. The stock last traded at ₹252, a market capitalisation of ₹879 crore, on a P/E of 29.2. Over the past 52 weeks the stock has ranged between ₹117 and ₹254. Figures are as of 6 Oct 2026 and are not real time.
Kilitch Drugs India Ltd share price and key metrics
- Current price
- ₹252
- Market cap
- ₹879 cr
- Stock P/E
- 29.2
- Book value
- ₹80
- ROE
- 10.6%
- ROCE
- 13.4%
- Dividend yield
- 0.00%
- 52w high / low
- 254/117
Metrics as of 6 Oct 2026. Not real time.
Track Kilitch Drugs India Ltd
Cruxal reads every Kilitch Drugs India Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Kilitch Drugs India Ltd growth and returns
- 10 Years
- 27%
- 5 Years
- 28%
- 3 Years
- 19%
- TTM
- 14%
- 10 Years
- 16%
- 5 Years
- 55%
- 3 Years
- 38%
- TTM
- 7%
- 10 Years
- 27%
- 5 Years
- 22%
- 3 Years
- 22%
- 1 Year
- 26%
- 10 Years
- 5%
- 5 Years
- 9%
- 3 Years
- 10%
- Last Year
- 11%
Kilitch Drugs India Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹44.88 cr, up 4.0% from ₹43.14 cr a year earlier. Net profit was ₹1.96 cr, down 13.7% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 47.47 | 56.17 | 61.23 | 43.14 | 48.92 | 53.81 | 89.6 | 44.88 |
| Expenses | 41.37 | 47.44 | 46.64 | 39.88 | 43.88 | 47.66 | 67.46 | 41.94 |
| Operating profit | 6.1 | 8.73 | 14.59 | 3.26 | 5.04 | 6.15 | 22.14 | 2.94 |
| OPM % | 12.85% | 15.54% | 23.83% | 7.56% | 10.30% | 11.43% | 24.71% | 6.55% |
| Other income | 5.16 | 1.73 | 1.7 | 2.56 | 6.66 | 1.53 | 0.49 | 2.9 |
| Interest | 0.31 | 1.4 | 1.6 | 1.53 | 1.44 | 1.15 | 1.44 | 0.88 |
| Depreciation | 0.61 | 0.81 | 0.85 | 0.84 | 0.86 | 0.94 | 0.98 | 1.09 |
| Profit before tax | 10.34 | 8.25 | 13.84 | 3.45 | 9.4 | 5.59 | 20.21 | 3.87 |
| Tax % | 16.73% | 32.00% | 26.23% | 34.49% | 14.47% | 22.90% | 26.37% | 48.84% |
| Net profit | 8.61 | 5.61 | 10.22 | 2.27 | 8.04 | 4.31 | 14.88 | 1.96 |
| EPS (₹) | 2.46 | 1.70 | 2.97 | 0.87 | 2.34 | 1.27 | 4.15 | 0.83 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Kilitch Drugs India Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 27 | 51 | 82 | 53 | 68 | 114 | 140 | 154 | 198 | 235 | 237 |
| Operating profit | -1 | 6 | 7 | 0 | 5 | 10 | 18 | 24 | 32 | 37 | 36 |
| OPM % | -2.0% | 11% | 9% | 0.8% | 8% | 9% | 13% | 16% | 16% | 16% | 15% |
| Net profit | -9 | 5 | 4 | 1 | 4 | 6 | 8 | 14 | 25 | 30 | 29 |
| EPS (₹) | -3.09 | 1.72 | 1.15 | 0.25 | 1.09 | 2.17 | 3.08 | 4.17 | 7.63 | 8.63 | 8.59 |
TTM is the trailing twelve months to the most recent quarter.
Kilitch Drugs India Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 13 | 14 | 15 | 15 | 15 | 16 | 16 | 16 | 16 | 35 |
| Reserves | 88 | 98 | 106 | 103 | 112 | 124 | 136 | 160 | 186 | 245 |
| Borrowings | 1 | 1 | 9 | 13 | 15 | 20 | 22 | 32 | 49 | 89 |
| Other liabilities | 11 | 15 | 13 | 12 | 61 | 50 | 46 | 32 | 61 | 89 |
| Total liabilities | 113 | 128 | 144 | 143 | 203 | 210 | 220 | 240 | 313 | 458 |
| Fixed assets | 33 | 33 | 32 | 32 | 30 | 65 | 64 | 62 | 64 | 67 |
| CWIP | 1 | 3 | 20 | 30 | 65 | 3 | 4 | 6 | 47 | 140 |
| Investments | 53 | 56 | 53 | 52 | 60 | 71 | 62 | 72 | 72 | 75 |
| Other assets | 26 | 35 | 38 | 30 | 47 | 71 | 90 | 100 | 129 | 176 |
| Total assets | 113 | 128 | 144 | 143 | 203 | 210 | 220 | 240 | 313 | 458 |
As reported by the company. Total assets equal total liabilities by construction.
Kilitch Drugs India Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1 | 1 | 0 | 4 | 46 | 6 | 3 | -2 | 18 | 24 |
| Cash from investing | -2 | -4 | -14 | -10 | -38 | -15 | 8 | -8 | -40 | -100 |
| Cash from financing | -0 | 6 | 17 | 1 | 2 | 7 | -1 | 9 | 13 | 82 |
| Net cash flow | -0 | 2 | 3 | -5 | 10 | -2 | 10 | -1 | -9 | 6 |
| Free cash flow | -0 | -2 | -19 | -6 | 9 | -2 | -1 | -8 | -29 | -76 |
| CFO / operating profit | -202% | 25% | 60% | 1,598% | 877% | 79% | 39% | 23% | 82% | 92% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Kilitch Drugs India Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | -9% | 5% | 6% | 1% | 3% | 6% | 10% | 13% | 16% | 13% |
| Debtor days | 196 | 148 | 86 | 109 | 122 | 132 | 142 | 149 | 156 | 186 |
| Inventory days | 84 | 39 | 36 | 70 | 35 | 28 | 10 | 18 | 53 | 33 |
| Days payable | 184 | 108 | 33 | 89 | 525 | 239 | 200 | 118 | 189 | 230 |
| Cash conversion cycle | 96 | 79 | 89 | 89 | -367 | -79 | -48 | 50 | 20 | -11 |
| Working capital days | 115 | 93 | 37 | 22 | -223 | -40 | -4 | 30 | 56 | 49 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Kilitch Drugs India Ltd shareholding pattern
Promoters held 63.77% at Jun 2026, down from 69.23% at Jun 2025. FIIs 0.12%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 69.23% | 69.23% | 69.23% | 69.23% | 63.77% | 63.77% | 63.77% | 63.77% |
| FIIs | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.12% |
| Public | 30.77% | 30.76% | 30.77% | 30.77% | 36.22% | 36.23% | 36.22% | 36.11% |
| No. of shareholders | 9,920 | 10,139 | 9,749 | 10,379 | 10,929 | 12,043 | 11,785 | 12,627 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Kilitch Drugs India Ltd corporate filings
- We are submitting herewith the certificate under regulation 74(5) of SEBI DP regulationsCompany Updatelow impact
- We are submitting herewith the intimation of closure of trading windowInsider Trading / SASTlow impact
- Kilitch Drugs (India) Ltd. Announces Successful Conclusion of 34th Annual General Meeting and Approval of All ResolutionsAGM/EGMlow impact
Cruxal's analysis: Kilitch Drugs (India) Ltd. has successfully concluded its 34th Annual General Meeting…
Read the full analysis - Kilitch Drugs (India) Ltd. Concludes 34th Annual General Meeting; Approves Financial Statements and Executive Performance PayAGM/EGMlow impact
Cruxal's analysis: Kilitch Drugs (India) Ltd. has successfully concluded its 34th Annual General Meeting…
Read the full analysis - Kilitch Drugs India Ltd submits Monitoring Agency ReportCompany Updatelow impact
Cruxal's analysis: Kilitch Drugs India Ltd has submitted its Monitoring Agency Report as per Regulation 30…
Read the full analysis - Kilitch Drugs (India) Ltd. Reports Q1 FY27 Financial Results with Significant YoY Revenue GrowthCompany Updatemedium impact
Cruxal's analysis: Kilitch Drugs (India) Ltd. has released its financial results for the quarter ended 30th…
Read the full analysis - Kilitch Drugs (India) Ltd. reports significant decline in Q1 FY2027 earnings with consolidated net profit falling to 1.97 croreResulthigh impact
Cruxal's analysis: Kilitch Drugs (India) Ltd. reported a weak performance for the quarter ended 30th June…
Read the full analysis - Kilitch Drugs (India) Ltd. schedules Board Meeting for August 13, 2026, to approve Q1 FY27 financial resultsBoard Meetinglow impact
Cruxal's analysis: Kilitch Drugs (India) Ltd. has formally intimated the stock exchanges regarding a Board…
Read the full analysis - Kilitch Drugs (India) Ltd. Notifies Publication of 34th AGM Details and FY26 Annual Report AvailabilityCompany Updatelow impact
Cruxal's analysis: Kilitch Drugs (India) Ltd. has announced the newspaper publication on August 4, 2026…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.